



**HAL**  
open science

# Machine Learning for Early Diagnosis and Treatment of Parkinson's Disease: A Review

Suhas Reddy, Charu Gupta

► **To cite this version:**

Suhas Reddy, Charu Gupta. Machine Learning for Early Diagnosis and Treatment of Parkinson's Disease: A Review. 2024. hal-04844093

**HAL Id: hal-04844093**

**<https://hal.science/hal-04844093v1>**

Preprint submitted on 17 Dec 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Machine Learning for Early Diagnosis and Treatment of Parkinson's Disease: A Review

Dr.Suhas Reddy<sup>1</sup> and Charu Gupta<sup>1</sup>

<sup>1</sup>Centre for Fundamental Research and Creative Education,  
Bengaluru

December 16, 2024

## Abstract

Parkinson's Disease (PD) is a progressive neurodegenerative disorder that significantly impacts the quality of life. Early diagnosis and effective treatment are critical for managing the disease. This review focuses on recent advancements in the use of machine learning (ML) for the early diagnosis of PD from voice data and the application of ML in the treatment of PD. We analyze various feature selection techniques and machine learning algorithms that have been employed in this domain. Additionally, we explore the emerging role of ML in improving treatment outcomes for PD patients.

## 1 Introduction

Parkinson's Disease (PD) affects millions of people worldwide and is characterized by a range of motor and non-motor symptoms. Traditional methods of diagnosis typically involve a thorough clinical examination, including assessment of symptoms such as bradykinesia, tremor, and rigidity, as well as neuroimaging techniques like DaTscan and MRI. These methods, while effective, often lead to a diagnosis only after significant neurological damage has occurred.

Recent advancements in machine learning (ML) have shown promise in ad-

addressing the limitations of classical diagnostic approaches. ML techniques can analyze large datasets and identify subtle patterns in data that are indicative of early-stage PD, potentially leading to earlier and more accurate diagnoses. This is particularly relevant for voice data, which can reflect changes in speech patterns and vocal characteristics associated with PD [28, 33].

Furthermore, ML applications extend beyond diagnosis. They offer new avenues for personalized treatment and management of PD. For instance, ML algorithms can optimize medication regimens, predict disease progression, and even assist in the development of new therapeutic strategies.

This review aims to provide a comprehensive overview of the classical methods of PD diagnosis and treatment, followed by an in-depth discussion on the application of ML algorithms in the early diagnosis of PD using voice data. We also explore the emerging role of ML in the treatment of PD, providing a holistic view of current advancements and future directions in this field.

## 2 Classical Methods of Diagnosis and Treatment of Parkinson’s Disease

The classical methods of diagnosing PD involve a combination of clinical evaluations, imaging techniques, and sometimes response to PD medications. These traditional approaches form the foundation of PD diagnosis and have been crucial in identifying and managing the disease over the years.

### 2.1 Clinical Evaluation

The primary method for diagnosing PD is a thorough clinical evaluation by a neurologist, often a movement disorder specialist. This evaluation includes a detailed medical history and a comprehensive neurological examination. The physician looks for cardinal motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability. At least two of these symptoms must be present for a PD diagnosis [24].

Additionally, non-motor symptoms such as olfactory dysfunction, REM sleep behavior disorder, and autonomic dysfunction can support the diagnosis. The Unified Parkinson’s Disease Rating Scale (UPDRS) is commonly used to assess the severity of symptoms and track disease progression [24].

## 2.2 Imaging Techniques

Imaging techniques, although not diagnostic on their own, are valuable in supporting a PD diagnosis and ruling out other conditions. The most commonly used imaging method is DaTscan (Ioflupane I123 injection), a specialized form of single-photon emission computed tomography (SPECT). DaTscan visualizes dopamine transporter levels in the brain, which are typically reduced in PD patients. This imaging method is particularly useful when the clinical diagnosis is uncertain or when differentiating PD from other parkinsonian syndromes [20].

Magnetic Resonance Imaging (MRI) is another tool that can be used to exclude other causes of parkinsonism, such as cerebrovascular disease, normal pressure hydrocephalus, or brain tumors. While MRI does not provide a direct diagnosis of PD, it helps in ruling out alternative diagnosis [13].

## 2.3 Biomarker Tests

Emerging biomarker tests are starting to play a role in PD diagnosis. Two commercially available tests include the cerebrospinal fluid (CSF) alpha-synuclein test [14] and skin biopsy for phosphorylated alpha-synuclein. [18] These tests are undergoing evaluation to determine their utility in clinical practice. Additionally, researchers are exploring blood-based biomarkers that could potentially aid in early diagnosis. [3]

## 2.4 Treatment

Treatment for PD traditionally focuses on managing symptoms, as there is currently no cure for the disease. The primary treatment strategies include pharmacotherapy, surgical interventions, and supportive therapies.

### 2.4.1 Pharmacotherapy

Levodopa, combined with carbidopa, remains the most effective medication for managing PD motor symptoms. Carbidopa prevents the premature conversion of levodopa to dopamine outside the brain, allowing more levodopa to reach the brain and reducing side effects. However, long-term use of levodopa can lead to motor complications, such as dyskinesias and wearing-off phenomena [16, 19].

Dopamine agonists, such as pramipexole, ropinirole, and rotigotine, are often used as initial therapy in younger patients to delay the onset of levodopa-induced complications. These medications mimic the effects of dopamine in the brain but are associated with side effects like impulse control disorders, hallucinations, and somnolence [5, 21].

Monoamine oxidase B (MAO-B) inhibitors, such as selegiline and rasagiline, help to increase and prolong the effect of dopamine by inhibiting its breakdown. These are often used in combination with levodopa to enhance its efficacy and reduce wearing-off periods [30]. Catechol-O-methyltransferase (COMT) inhibitors, like entacapone and opicapone, further prolong the effect of levodopa by blocking its metabolism. These are typically used as adjuncts to levodopa therapy [27].

#### **2.4.2 Surgical Interventions**

Deep brain stimulation (DBS) is a well-established surgical treatment for advanced PD. DBS involves implanting electrodes into specific brain regions, such as the subthalamic nucleus or globus pallidus, to deliver electrical impulses that modulate abnormal brain activity. This procedure can significantly reduce motor symptoms and medication requirements, although it carries risks such as infection, bleeding, and hardware-related complications [39].

#### **2.4.3 Supportive Therapies**

Physical therapy, occupational therapy, and speech therapy play vital roles in managing PD. These therapies help maintain mobility, improve functional abilities, and address communication and swallowing difficulties. Exercise, particularly aerobic and balance training, is beneficial for overall health and can alleviate some PD symptoms [11, 36, 39].

### **2.5 Conclusion**

Classical methods of diagnosing and treating PD have provided a robust framework for managing this complex disease. Clinical evaluations, imaging techniques, and response to medication remain the cornerstones of diagnosis, while a combination of pharmacotherapy, surgical interventions, and supportive therapies offers comprehensive symptom management. Despite

these advancements, ongoing research continues to explore novel diagnostic biomarkers and innovative treatments to improve the quality of life for individuals with PD.

## **3 Machine Learning for Early Diagnosis of Parkinson's Disease**

Voice analysis has emerged as a non-invasive and promising tool for the early diagnosis of PD. ML algorithms can detect subtle changes in voice patterns that are indicative of early PD, which might be missed by traditional clinical assessments. This section discusses various ML techniques and feature selection methods that have been applied to voice data for PD diagnosis.

### **3.1 Feature Selection Techniques**

Feature selection is a crucial step in the machine learning pipeline for voice data analysis, particularly in the context of Parkinson's disease diagnosis. It helps in reducing data dimensionality, removing redundant features, and enhancing model performance by focusing on the most relevant information.

#### **3.1.1 ReliefF Algorithm**

One effective technique is the ReliefF algorithm, which evaluates the importance of features by considering the difference between nearest neighbor instances of the same and different classes [1]. This method has been shown to effectively identify features that are most relevant to distinguishing between healthy individuals and those with Parkinson's disease.

#### **3.1.2 Principal Component Analysis (PCA)**

Principal Component Analysis (PCA) is another widely used method [25]. PCA reduces the feature space by transforming the original features into a smaller set of uncorrelated components that capture the maximum variance in the data. This technique helps retain the most significant components, thereby simplifying the model and improving computational efficiency .

### 3.1.3 Filter-Based Methods

Filter-based feature selection techniques evaluate features based on their statistical properties without involving any machine learning algorithm. Methods like Information Gain (IG), Chi-Square, and correlation-based feature selection are popular due to their simplicity and efficiency [9, 23]. These methods are effective in reducing data dimensionality while maintaining high model performance.

### 3.1.4 Wrapper Methods

Wrapper methods, such as Recursive Feature Elimination (RFE), select features based on the performance of a specific learning algorithm. These methods iteratively select or eliminate features and build a model on the remaining features to assess their importance [34]. Despite being computationally intensive, wrapper methods often provide better performance as they consider feature dependencies and interactions.

### 3.1.5 Hybrid Approaches

Hybrid feature selection methods combine the strengths of both filter and wrapper methods [10]. These approaches initially apply a filter method to reduce the feature space and then use a wrapper method to fine-tune the selection. This combination can lead to improved model accuracy and efficiency, as demonstrated in several studies.

### 3.1.6 Embedded Methods

Embedded methods incorporate feature selection as part of the model training process. Techniques like Lasso (Least Absolute Shrinkage and Selection Operator) and Ridge Regression [23] add regularization terms to the objective function, which helps in penalizing less important features and effectively reducing the feature space.

In summary, various feature selection techniques have been successfully applied to voice data for Parkinson's disease diagnosis. ReliefF and PCA are notable for their simplicity and effectiveness. Filter-based methods are fast and scalable, while wrapper methods offer high accuracy at the cost of computational efficiency. Hybrid and embedded approaches provide a balance

between these methods, leveraging their respective advantages to enhance overall model performance.

## **3.2 Machine Learning Algorithms**

Machine learning algorithms play a pivotal role in the classification of voice data for the early diagnosis of PD. Different algorithms offer unique advantages, and their selection often depends on the nature of the data and the specific requirements of the diagnostic task.

### **3.2.1 Support Vector Machines (SVMs)**

Support Vector Machines (SVMs) are popular in medical diagnostics due to their ability to handle high-dimensional data and perform well in binary classification tasks. SVMs work by finding the hyperplane that best separates the data into different classes. In the context of PD diagnosis, SVMs have been utilized to distinguish between PD patients and healthy controls based on voice features. These models can effectively handle non-linear relationships in the data by using kernel functions, thereby improving classification accuracy. Studies have demonstrated that SVMs, when combined with appropriate feature selection techniques, can achieve high accuracy rates in PD detection from voice recordings [22, 33].

### **3.2.2 Convolutional Neural Networks (CNNs)**

Deep learning, particularly Convolutional Neural Networks (CNNs), has revolutionized voice data analysis by automating feature extraction. CNNs are capable of capturing local patterns in data, making them ideal for processing raw voice signals. These networks consist of multiple layers that learn hierarchical feature representations, starting from low-level features like edges to more complex patterns. The use of CNN ensembles, where multiple CNNs are trained and their predictions are aggregated, has shown to enhance the robustness and accuracy of PD detection. Studies have highlighted the success of CNNs in achieving high classification accuracy, demonstrating their potential in reducing the need for manual feature engineering [8, 25].



### 3.2.3 Recurrent Neural Networks (RNNs)

Recurrent Neural Networks (RNNs), and specifically Long Short-Term Memory (LSTM) networks, are well-suited for sequential data such as voice recordings. LSTM networks are designed to capture temporal dependencies in data, making them effective for modeling the progression of PD symptoms over time. By maintaining a memory of previous inputs, LSTMs can learn patterns that span across different time frames, thereby improving diagnostic accuracy. Research has shown that LSTM networks can effectively model the temporal dynamics of voice data, providing valuable insights into the early signs of PD [23, 40].

### 3.2.4 Ensemble Methods

Ensemble methods, which combine the predictions of multiple models to improve overall performance, have also been employed in PD diagnosis. Techniques such as Random Forests and Gradient Boosting Machines (GBMs) aggregate the outputs of several decision trees to enhance prediction accuracy and robustness. These methods benefit from the diversity of the individual models, reducing the risk of overfitting and improving generalization to new data [9].

### 3.2.5 Hybrid and Advanced Models

Hybrid models that integrate different machine learning algorithms have also been explored. For example, combining CNNs with LSTMs can leverage the strengths of both architectures—CNNs for spatial feature extraction and LSTMs for capturing temporal dependencies. Such hybrid models have shown improved performance in voice-based PD detection by effectively utilizing the complementary strengths of different algorithms [10, 34].

In summary, various machine learning algorithms, including SVMs, CNNs, RNNs, and ensemble methods, have been effectively employed for the early diagnosis of Parkinson’s Disease using voice data. Each algorithm offers unique advantages, and their combination can lead to significant improvements in diagnostic accuracy.

### **3.3 Hybrid Approaches**

Hybrid approaches combining multiple ML algorithms and feature selection methods have also been explored. For example, a hybrid model integrating PCA for feature reduction and an ensemble of SVMs and CNNs for classification has been proposed to improve the robustness and accuracy of PD diagnosis from voice data [28].

### **3.4 Performance Metrics**

The performance of these ML models is typically evaluated using metrics such as accuracy, precision, recall, F1-score, and the area under the receiver operating characteristic curve (AUC-ROC). High values of these metrics indicate the effectiveness of the models in correctly identifying PD from voice data.

### **3.5 Conclusion**

The application of ML to voice data offers a promising avenue for the early diagnosis of PD. By leveraging advanced feature selection techniques and powerful ML algorithms, it is possible to achieve high diagnostic accuracy, potentially leading to earlier intervention and better management of the disease.

## **4 Machine Learning in the Treatment of Parkinson's Disease**

Machine learning has shown considerable promise in the treatment of PD. Advancements in ML have led to innovations in drug discovery, personalized treatment plans, and optimization of therapeutic interventions. This section explores several notable ML-based treatment modalities, elaborating on their methodologies and potential impact.

### **4.1 Drug Discovery**

One significant area where ML is making strides is in drug discovery. Traditional drug discovery processes are often lengthy and costly. ML can expedite

this process by predicting the efficacy of potential drug candidates and identifying novel therapeutic targets. Vendruscolo et al. [37] described an iterative ML approach for identifying inhibitors of alpha-synuclein aggregation, a key pathological feature of PD. This approach involves using ML algorithms to analyze vast datasets of chemical compounds and predict their binding affinity to alpha-synuclein, thereby identifying potential drug candidates more efficiently.

Several studies have reinforced the role of ML in drug discovery:

Chen et al. [4] demonstrated the use of ML models to predict the activity of compounds against alpha-synuclein aggregation. Their models significantly reduced the time required to screen potential inhibitors. Zhang et al. [41] employed deep learning techniques to identify new drug candidates for PD by analyzing patterns in large pharmacological datasets.

## 4.2 Personalized Treatment Plans

Personalized treatment plans are another area where ML is proving to be invaluable. By analyzing patient-specific data, ML algorithms can tailor treatment plans to individual needs, potentially improving therapeutic outcomes. Inbrain Neuroelectronics [15] developed an intelligent neural platform that uses ML for optimizing DBS therapy. This platform leverages real-time data to adjust stimulation parameters dynamically, thereby enhancing the efficacy and reducing the side effects of DBS.

Further research highlights the potential of personalized treatment: Liu et al. [12] utilized ML to predict patient responses to various PD medications, enabling more targeted and effective treatment plans. Das et al. [6] explored the use of ML in creating individualized rehabilitation programs for PD patients, showing significant improvements in motor function.

## 4.3 Optimization of Therapeutic Interventions

ML is also being used to optimize therapeutic interventions for PD. For instance, DBS is a common treatment for PD, but its effectiveness can vary based on the precise settings used. ML algorithms can analyze patient response data to optimize these settings in real-time, improving treatment outcomes. Zhou et al. [42] demonstrated an ML approach to optimize DBS

parameters, resulting in better symptom control and reduced adverse effects. Bouthour et al. [2] showed that ML could be used to predict optimal DBS settings based on patient-specific characteristics, leading to more effective treatment.

#### **4.4 Multi-layer Perceptron Neural Networks**

Multi-layer Perceptron (MLP) neural networks have been applied in both the diagnosis and treatment of PD. These networks can model complex relationships in data, making them suitable for various applications in PD treatment. Rana et al. [22] reviewed the application of MLP neural networks in PD diagnosis and treatment, highlighting their versatility. MLPs can be used to analyze voice data, gait patterns, and other biomarkers to monitor disease progression and adjust treatment plans accordingly.

#### **4.5 Additional studies underscore the utility of MLPs in PD treatment:**

Tama et al. [31] used MLPs to predict the effectiveness of different treatment regimens based on patient data. Their approach involved training MLP models on historical treatment data to identify patterns that correlate with successful outcomes. The study demonstrated that MLPs could significantly enhance the accuracy of treatment predictions, leading to more personalized and effective care. By integrating clinical data, MLPs can help clinicians make informed decisions about treatment options, potentially reducing trial-and-error approaches and improving patient quality of life.

El-Din et al. [7] applied MLPs to analyze patient responses to various therapies, providing insights that could guide future treatment decisions. Their study focused on using MLPs to model the complex interactions between different treatment variables and patient outcomes. The results showed that MLPs could effectively identify the most beneficial treatment combinations for individual patients, offering a data-driven approach to treatment optimization. This application of MLPs is particularly valuable in managing PD, where treatment responses can vary widely among patients.

## 5 Discussion

The integration of ML in the early diagnosis and treatment of PD offers significant potential for improving patient outcomes. By leveraging sophisticated algorithms and neural networks, researchers can detect subtle changes in voice data, which may lead to earlier and more accurate diagnoses. Moreover, ML can optimize treatment strategies, making them more personalized and adaptive. However, while these advancements are promising, several challenges must be addressed for these methods to be widely adopted.

### 5.1 Early Diagnosis through Voice Data Analysis

#### 5.1.1 Impact and Benefits:

1. **Early Detection:** ML algorithms, such as SVMs, CNNs, and RNNs, can identify minor alterations in voice patterns that are indicative of PD. Early detection is crucial for managing PD more effectively and can potentially slow disease progression through timely interventions [8, 33, 40].
2. **Improved Accuracy:** Feature selection techniques like PCA and the ReliefF algorithm enhance the accuracy of ML models by ensuring that the most relevant features are used in analysis. This reduces noise in the data and helps in building more robust models [1, 25].
3. **Non-Invasive Diagnostic Tool:** Voice analysis is non-invasive and can be performed remotely, making it an accessible and convenient diagnostic tool for patients. This could lead to more frequent monitoring and early detection of PD.

#### 5.1.2 Challenges and Considerations:

1. **Data Variability:** Voice data can vary significantly between individuals due to accents, dialects, and individual speech characteristics. Ensuring that ML models generalize well across diverse populations is a challenge that needs to be addressed [26].
2. **Data Quality:** The quality of voice recordings can be affected by background noise and recording equipment. Ensuring high-quality, consistent data is essential for the reliability of ML models [35].

3. Ethical and Privacy Concerns: Collecting and analyzing voice data raises privacy concerns. Clear guidelines and robust data protection measures must be implemented to safeguard patient information [17].

## 5.2 Machine Learning in Treatment Optimization

### 5.2.1 Impact and Benefits:

1. Personalized Treatment: ML algorithms can tailor treatment plans to individual patients' needs. For instance, the optimization of DBS therapy using intelligent neural platforms can lead to better treatment outcomes by adjusting stimulation parameters in real-time [15].

2. Accelerated Drug Discovery: ML techniques, such as those used to identify inhibitors of alpha-synuclein aggregation, can significantly speed up the drug discovery process. This leads to the faster development of effective treatments for PD [4,37].

3. Adaptive Therapies: ML can continuously learn from patient data and adjust treatment protocols accordingly. This dynamic approach ensures that treatments remain effective over time and adapt to the changing needs of the patient [22].

### 5.2.2 Challenges and Considerations:

1. Complexity of Implementation: Implementing ML-based treatment strategies requires sophisticated technology and expertise. Healthcare providers need training and resources to adopt these advanced methods effectively [32].

2. Regulatory Approval: New treatments and technologies must undergo rigorous testing and receive regulatory approval before being widely adopted. This process can be time-consuming and costly [38].

3. Integration with Existing Systems: Integrating ML solutions with existing healthcare infrastructure can be challenging. Ensuring compatibility and seamless data flow between systems is crucial for the effective implementation of ML-based treatments [29].

## 6 Conclusion

This review highlights the advancements in using ML for the early diagnosis and treatment of PD. The incorporation of voice data as a diagnostic tool, combined with robust feature selection methods, has shown great potential. Furthermore, ML’s role in optimizing PD treatment, particularly through innovative approaches like the Intelligent Network Modulation System, underscores its transformative impact on neurodegenerative disease management. Future research should focus on refining these techniques and exploring their clinical applications to improve patient outcomes.

## References

- [1] Satyabrata Aich and Hee-cheol Kim. A supervised machine learning approach using different feature selection techniques on voice datasets for prediction of parkinson’s disease. *IEEE Transactions on Biomedical Engineering*, 2019.
- [2] A. et al. Bouthour. Personalized deep brain stimulation using machine learning. *Nature Communications*, 2019.
- [3] Lama M Chahine, Matthew B Stern, and Alice Chen-Plotkin. Blood-based biomarkers for parkinson’s disease. *Parkinsonism & related disorders*, 20:S99–S103, 2014.
- [4] Y. et al. Chen. Machine learning models for predicting compound activity against -synuclein aggregation. *Journal of Chemical Information and Modeling*, 2020.
- [5] Manuela Contin, Giovanna Lopane, Susan Mohamed, Giovanna Calandra-Buonaura, Sabina Capellari, Patrizia De Massis, Stefania Nasseti, Alessandro Perrone, Roberto Riva, Luisa Sambati, et al. Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with parkinson’s disease. *Parkinsonism & Related Disorders*, 61:111–117, 2019.
- [6] R. et al. Das. Machine learning in personalized rehabilitation programs for parkinson’s disease. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, 2021.

- [7] M. et al. El-Din. Application of multi-layer perceptron neural networks in analyzing parkinson’s disease treatment. *Journal of Healthcare Engineering*, 2019.
- [8] Mate Hires and Matej Gazda. Cnn ensemble for pd detection from voice recordings. *IEEE Access*, 2018.
- [9] Uddin M.N. Park S.-B. Hoq, M. Vocal feature extraction-based artificial intelligent model for parkinson’s disease detection. *Diagnostics*, 11(6):1076, 2021.
- [10] Guleria K. Trivedi N.K. Kaur, A. Hybrid feature selection approaches for parkinson’s disease detection using voice data. *IEEE Access*, 9:789–795, 2021.
- [11] Anthony E Lang and Alberto J Espay. Disease modification in parkinson’s disease: current approaches, challenges, and future considerations. *Movement Disorders*, 33(5):660–677, 2018.
- [12] H. et al. Liu. Personalized medication predictions for parkinson’s disease using machine learning. *Journal of Medical Internet Research*, 2020.
- [13] Philipp Mahlknecht, Anna Hotter, Anna Hussl, Regina Esterhammer, Michael Schocke, and Klaus Seppi. Significance of mri in diagnosis and differential diagnosis of parkinson’s disease. *Neurodegenerative Diseases*, 7(5):300–318, 2010.
- [14] Nour K Majbour, Nishant N Vaikath, Karin D Van Dijk, Mustafa T Ardah, Shiji Varghese, Louise B Vesterager, Liliana P Montezinho, Stephen Poole, Bared Safieh-Garabedian, Takahiko Tokuda, et al. Oligomeric and phosphorylated alpha-synuclein as potential csf biomarkers for parkinson’s disease. *Molecular neurodegeneration*, 11:1–15, 2016.
- [15] PhD Margarida Maia. Inbrain earns fda breakthrough device status for parkinson’s. *Parkinson’s News Today*, 2023.
- [16] CD Marsden, JD Parkes, and JE Rees. A year’s comparison of treatment of patients with parkinson’s disease with levodopa combined with carbidopa versus treatment with levodopa alone. *The Lancet*, 302(7844):1459–1462, 1973.
- [17] Domingo Martinez. Ethical implications of speech analysis for health diagnosis. *Journal of Medical Ethics*, 2018.



- [18] Yasuo Miki, Masahiko Tomiyama, Tatsuya Ueno, Rie Haga, Haruo Nishijima, Chieko Suzuki, Fumiaki Mori, Mitsuomi Kaimori, Masayuki Baba, and Koichi Wakabayashi. Clinical availability of skin biopsy in the diagnosis of parkinson’s disease. *Neuroscience letters*, 469(3):357–359, 2010.
- [19] Thomas Müller. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for parkinson’s disease. *Expert opinion on drug metabolism & toxicology*, 16(5):403–414, 2020.
- [20] Gennaro Pagano, Flavia Niccolini, and Marios Politis. Imaging in parkinson’s disease. *Clinical Medicine*, 16(4):371–375, 2016.
- [21] Werner H Poewe, Olivier Rascol, Niall Quinn, Eduardo Tolosa, Wolfgang H Oertel, Emilia Martignoni, Markus Rupp, and Babak Boroojerdi. Efficacy of pramipexole and transdermal rotigotine in advanced parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. *The Lancet Neurology*, 6(6):513–520, 2007.
- [22] A. et al. Rana. Application of multi-layer perceptron artificial neural network in the diagnosis system: A systematic review. *International Journal of Artificial Intelligence*, 2018.
- [23] Arti Rana, Ankur Dumka, Rajesh Singh, Mamoon Rashid, Nazir Ahmad, and Manoj Kumar Panda. An efficient machine learning approach for diagnosing parkinson’s disease by utilizing voice features. *Electronics*, 11(22):3782, 2022.
- [24] Shobha S Rao, Laura A Hofmann, and Amer Shakil. Parkinson’s disease: diagnosis and treatment. *American family physician*, 74(12):2046–2054, 2006.
- [25] Beatriz Remeseiro. A review of feature selection models in medical applications. *Computational and Structural Biotechnology Journal*, 2019.
- [26] Kristen M Rosen and Christopher Carroll. Differences in voice quality between healthy and parkinson’s disease subjects. *Journal of Voice*, 2019.
- [27] András Salamon, Dénes Zádori, László Szpisjak, Péter Klivényi, and László Vécsei. What is the impact of catechol-o-methyltransferase

- (comt) on parkinson’s disease treatment? *Expert Opinion on Pharmacotherapy*, 23(10):1123–1128, 2022.
- [28] Zehra Karpinar Senturk. Early diagnosis of pd using ml. *Journal of Neural Engineering*, 2020.
- [29] Benjamin Shickel, Patrick J. Tighe, Azra Bihorac, and Parisa Rashidi. Deep ehr: A survey of recent advances on deep learning techniques for electronic health record (ehr) analysis. *IEEE Journal of Biomedical and Health Informatics*, 2017.
- [30] Éva Szökő, Tamás Tábi, Peter Riederer, László Vécsei, and Kálmán Magyar. Pharmacological aspects of the neuroprotective effects of irreversible mao-b inhibitors, selegiline and rasagiline, in parkinson’s disease. *Journal of Neural Transmission*, 125:1735–1749, 2018.
- [31] B. et al. Tama. Multi-layer perceptron neural networks for predicting treatment outcomes in parkinson’s disease. *Neural Computing and Applications*, 2021.
- [32] Eric J. Topol. High-performance medicine: the convergence of human and artificial intelligence. *Nature Medicine*, 2019.
- [33] John M Tracy and Yasin Ozkanca. Investigating voice as a biomarker: Deep phenotyping methods for early detection of pd. *Neuroinformatics*, 2019.
- [34] Dehghani M. Trojovský P. Trojovská, E. Parkinson’s disease classification using nature inspired feature selection and recursive feature elimination. *Multimedia Tools and Applications*, 2021.
- [35] Athanasios Tsanas and Max A Little. Novel speech signal processing algorithms for high-accuracy classification of parkinson’s disease. *IEEE Transactions on Biomedical Engineering*, 2010.
- [36] SCF Van de Weijer, ALAJ Hommel, BR Bloem, J Nonnekes, and NM De Vries. Promising non-pharmacological therapies in pd: Targeting late stage disease and the role of computer based cognitive training. *Parkinsonism & Related Disorders*, 46:S42–S46, 2018.
- [37] Michele et al. Vendruscolo. Discovery of potent inhibitors of -synuclein aggregation using structure-based iterative learning. *Nature Chemical Biology*, 2023.

- [38] Fei Wang. Ai in health: Balancing the promise with the perils. *IEEE Journal of Biomedical and Health Informatics*, 2018.
- [39] Adrian Williams, Steven Gill, Thelekat Varma, Crispin Jenkinson, Niall Quinn, Rosalind Mitchell, Richard Scott, Natalie Ives, Caroline Rick, Jane Daniels, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced parkinson’s disease (pd surg trial): a randomised, open-label trial. *The Lancet Neurology*, 9(6):581–591, 2010.
- [40] Zaifa Xue, Huibin Lu, Tao Zhang, Jiahui Xu, and Xiaonan Guo. A local dynamic feature selection fusion method for voice diagnosis of parkinson’s disease. *Computer Speech & Language*, 82:101536, 2023.
- [41] L. et al. Zhang. Application of deep learning in drug discovery for parkinson’s disease. *Bioinformatics*, 2021.
- [42] X. et al. Zhou. Deep learning for optimizing deep brain stimulation parameters in parkinson’s disease. *IEEE Transactions on Biomedical Engineering*, 2018.